{"organizations": [], "uuid": "bc21534bc263190e39f64e234cb4d0813e5aaba2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180326.html", "section_title": "Archive News &amp; Video for Monday, 26 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/roche-tecentriq/roches-tecentriq-cocktail-helps-lung-cancer-patients-live-longer-idUSFWN1R701A", "country": "US", "domain_rank": 408, "title": "Roche's Tecentriq cocktail helps lung cancer patients live longer", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.998, "site_type": "news", "published": "2018-03-26T13:15:00.000+03:00", "replies_count": 0, "uuid": "bc21534bc263190e39f64e234cb4d0813e5aaba2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/roche-tecentriq/roches-tecentriq-cocktail-helps-lung-cancer-patients-live-longer-idUSFWN1R701A", "ord_in_thread": 0, "title": "Roche's Tecentriq cocktail helps lung cancer patients live longer", "locations": [], "entities": {"persons": [{"name": "roche", "sentiment": "negative"}, {"name": "tecentriq", "sentiment": "negative"}, {"name": "brenna hughes neghaiwi", "sentiment": "none"}, {"name": "john miller", "sentiment": "none"}], "locations": [{"name": "zurich", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "roche", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "ZURICH, March 26 (Reuters) - Swiss drugmaker Rocheâ€™s immunotherapy Tecentriq combined with other medicines helped people with advanced lung cancer live longer, compared to patients receiving an older drug combination, the company said in a statement on Monday.\nTreatment mixing Tecentriq with Avastin and chemotherapies carboplatin and paclitaxel boosted overall survival in first-line treatment, compared to patients who received Avastin plus carboplatin and paclitaxel. Roche said it would submit the data to authorities and hopes for a quick approval. (Reporting by John Miller; editing by Brenna Hughes Neghaiwi)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-26T13:15:00.000+03:00", "crawled": "2018-03-27T11:38:49.014+03:00", "highlightTitle": ""}